Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis
AD is a relapsing and remitting skin disease often requiring long‐term treatment. We assessed the long‐term efficacy of tralokinumab in adults with moderate‐to‐severe AD consistently treated for up to 4 years. Treatment with tralokinumab plus optional TCS/TCI provided substantial improvements in AD signs and symptoms, and these improvements were ...
Melinda Gooderham +13 more
wiley +1 more source
Analysis of corneal biomechanical characteristics and clinical correlations in children with dust mite-allergic conjunctivitis. [PDF]
Zhu Y +7 more
europepmc +1 more source
Ocular Allergy Within the Framework of the EAACI Nomenclature of Allergic Diseases and Hypersensitivity Reactions. [PDF]
Bogacka E +7 more
europepmc +1 more source
Screening and surveillance for ophthalmic disorders and visual deficits in children at a tertiary care hospital in Central India. [PDF]
Gaikwad S, Saoji C, Nagrale P.
europepmc +1 more source
Global Perspectives on Therapy for Noninfectious Conjunctival Hyperemia: A Narrative Review. [PDF]
Toyos M +9 more
europepmc +1 more source
An Unusual Localized Reaction of Conjunctivitis with Systemic Use of Ketoprofen: A Case Report. [PDF]
Araujo MAR.
europepmc +1 more source
Sexual Dimorphism in Allergic and Mast Cell-Associated Diseases. [PDF]
Kotha A +8 more
europepmc +1 more source
Allergic Reactions to Brimonidine 0.15%: A Case Series. [PDF]
Mat Nawi FN, Bastion MC.
europepmc +1 more source
Clinical profile of ocular allergy and its impact on quality of life in Brazilian children and adolescents. [PDF]
Marino LM +6 more
europepmc +1 more source
IL-18 receptor axis in allergic conjunctivitis: a multi-omics study. [PDF]
Yuan L +7 more
europepmc +1 more source

